國立虎尾科技大學 |

Myeloid-Derived Suppressor Cells and Cancer

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Myeloid-Derived Suppressor Cells and Cancer/ by David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan.
作者:	Escors, David.
其他作者:	Talmadge, James E.
面頁冊數:	IX, 102 p. 8 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Immunology. -
電子資源:	https://doi.org/10.1007/978-3-319-26821-7
ISBN:	9783319268217

Myeloid-Derived Suppressor Cells and Cancer
Escors, David.

Myeloid-Derived Suppressor Cells and Cancer[electronic resource] /by David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan. - 1st ed. 2016. - IX, 102 p. 8 illus. in color.online resource. - SpringerBriefs in Immunology,2194-2773. - SpringerBriefs in Immunology,.

Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.

The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.

ISBN: 9783319268217

Standard No.: 10.1007/978-3-319-26821-7doiSubjects--Topical Terms:

592892
Immunology.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Myeloid-Derived Suppressor Cells and Cancer
LDR:02654nam a22003975i 4500 001 974886
003 DE-He213
005 20200706082315.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319268217 $9 978-3-319-26821-7
024 7 $a 10.1007/978-3-319-26821-7 $2 doi
035 $a 978-3-319-26821-7
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
100 1 $a Escors, David. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 891044
245 1 0 $a Myeloid-Derived Suppressor Cells and Cancer $h [electronic resource] / $c by David Escors, James E. Talmadge, Karine Breckpot, Jo A. Van Ginderachter, Grazyna Kochan.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a IX, 102 p. 8 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a SpringerBriefs in Immunology, $x 2194-2773
505 0 $a Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
520 $a The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
650 0 $a Immunology. $3 592892
650 0 $a Cancer research. $3 1253664
650 0 $a Oncology . $3 1253469
650 0 $a Cell biology. $3 1253486
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Oncology. $3 593951
650 2 4 $a Cell Biology. $3 593889
700 1 $a Talmadge, James E. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1269547
700 1 $a Breckpot, Karine. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1269548
700 1 $a Van Ginderachter, Jo A. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1269549
700 1 $a Kochan, Grazyna. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1269550
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319268194
776 0 8 $i Printed edition: $z 9783319268200
830 0 $a SpringerBriefs in Immunology, $x 2194-2773 $3 1262382
856 4 0 $u https://doi.org/10.1007/978-3-319-26821-7
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)